-
公开(公告)号：US20210402083A1
公开(公告)日：2021-12-30
申请号：US17386659
申请日：2021-07-28
Applicant: AMGEN INC.
Inventor： Scott R. Gibson , Sheldon B. Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , Lawton Laurence , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Ian P. Dardani , Sean M. O'connor , Danielle Feldman
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.
-
公开(公告)号：US11266777B2
公开(公告)日：2022-03-08
申请号：US16071873
申请日：2017-02-13
Applicant: AMGEN INC.
Inventor： Scott R. Gibson , Sheldon B. Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Sean M. O'connor , Robert Decker , Gautam N. Shetty , Ryan M. Agard , Nicholas J. Ciccarelli , Daniel Davenport
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.
-
公开(公告)号：US11129936B2
公开(公告)日：2021-09-28
申请号：US16089685
申请日：2017-04-07
Applicant: AMGEN INC.
Inventor： Scott R. Gibson , Sheldon B. Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , Lawton Laurence , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Ian P. Dardani , Sean M. O'connor , Danielle Feldman
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.
-
公开(公告)号：US10569014B2
公开(公告)日：2020-02-25
申请号：US15552828
申请日：2016-03-02
Applicant: AMGEN INC.
Inventor： Ian B. Hanson , Lawton Laurence , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Danielle Feldman , Matthew J. Clemente
Abstract: The present invention provides devices and methods for establishing aseptic connections between two or more components or subassemblies. The devices may be used in medical devices such as drug delivery pumps (10). In some embodiments, a connection is made between a drug container (50, 1050, 2050) and a fluid pathway connection assembly (300, 1300, 2300). The fluid pathway connection assembly may include a connection hub (312, 1312, 2312), a piercing member (316, 1316, 2316), and a piercing member retainer (314, 1314, 2314). The assembly may further include a first film (318, 1318, 2318) covering a cavity (312A, 1312A, 2312A), thereby maintaining the aseptic condition of the cavity. The drug container may hold a fluid drug and include a pierceable seal (326, 1326, 2326). A second film (322, 1322, 2322) may cover a recess (328, 1328, 2328) formed by the seal and thereby maintain the aseptic condition of the interior of the chamber. The piercing member may be caused to pierce the first and second film and the pierceable seal to open a fluid pathway for delivery of the fluid drug through the fluid pathway connection assembly.
-
Patent Agency Ranking
公开(公告)号：US20200155759A1
公开(公告)日：2020-05-21
申请号：US16752075
申请日：2020-01-24
Applicant: AMGEN INC.
Inventor： Ian B. Hanson , Lawton Laurence , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Danielle Feldman , Matthew J. Clemente
Abstract: The present invention provides devices and methods for establishing aseptic connections between two or more components or subassemblies. The devices may be used in medical devices such as drug delivery pumps (10). In some embodiments, a connection is made between a drug container (50, 1050, 2050) and a fluid pathway connection assembly (300, 1300, 2300). The fluid pathway connection assembly may include a connection hub (312, 1312, 2312), a piercing member (316, 1316, 2316), and a piercing member retainer (314, 1314, 2314). The assembly may further include a first film (318, 1318, 2318) covering a cavity (312A, 1312A, 2312A), thereby maintaining the aseptic condition of the cavity. The drug container may hold a fluid drug and include a pierceable seal (326, 1326, 2326). A second film (322, 1322, 2322) may cover a recess (328, 1328, 2328) formed by the seal and thereby maintain the aseptic condition of the interior of the chamber. The piercing member may be caused to pierce the first and second film and the pierceable seal to open a fluid pathway for delivery of the fluid drug through the fluid pathway connection assembly.
-
公开(公告)号：US20180028747A1
公开(公告)日：2018-02-01
申请号：US15552828
申请日：2016-03-02
Applicant: Matthew J. CLEMENTE , AMGEN INC.
Inventor： Ian B. Hanson , Lawton Laurence , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Danielle Feldman , Matthew J. Clemente
CPC classification number: A61M5/162 , A61J1/1406 , A61J1/201 , A61J1/2051 , A61M5/1413 , A61M5/142 , A61M5/14248 , A61M5/1456 , A61M5/158 , A61M5/1626 , A61M5/32 , A61M39/18 , A61M2005/14252 , A61M2005/1585 , A61M2005/2474 , A61M2005/341 , A61M2205/0216 , A61M2205/18 , A61M2205/581 , A61M2205/587
Abstract: The present invention provides devices and methods for establishing aseptic connections between two or more components or subassemblies. The devices may be used in medical devices such as drug delivery pumps (10). In some embodiments, a connection is made between a drug container (50, 1050, 2050) and a fluid pathway connection assembly (300, 1300, 2300). The fluid pathway connection assembly may include a connection hub (312, 1312, 2312), a piercing member (316, 1316, 2316), and a piercing member retainer (314, 1314, 2314). The assembly may further include a first film (318, 1318, 2318) covering a cavity (312A, 1312A, 2312A), thereby maintaining the aseptic condition of the cavity. The drug container may hold a fluid drug and include a pierceable seal (326, 1326, 2326). A second film (322, 1322, 2322) may cover a recess (328, 1328, 2328) formed by the seal and thereby maintain the aseptic condition of the interior of the chamber. The piercing member may be caused to pierce the first and second film and the pierceable seal to open a fluid pathway for delivery of the fluid drug through the fluid pathway connection assembly.
-
公开(公告)号：US12201809B2
公开(公告)日：2025-01-21
申请号：US17386659
申请日：2021-07-28
Applicant: AMGEN INC.
Inventor： Scott R. Gibson , Sheldon B. Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , Lawton Laurence , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Ian P. Dardani , Sean M. O'connor , Danielle Feldman
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.
-
公开(公告)号：US20220218900A1
公开(公告)日：2022-07-14
申请号：US17688578
申请日：2022-03-07
Applicant: AMGEN INC.
Inventor： Scott R. Gibson , Sheldon B, Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Sean M. O'connor , Robert Decker , Gautam N. Shetty , Ryan M. Agard , Nicholas J. Ciccarelli , Daniel Davenport
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.
-
公开(公告)号：US20200316291A1
公开(公告)日：2020-10-08
申请号：US16089685
申请日：2017-04-07
Applicant: AMGEN INC.
Inventor： Scott Robert Gibson , Sheldon B. Moberg , Basel Hasan Taha , Margaux Frances Boyaval , Mark A. Destefano , Lawton Laurence , John C. Love , Ian B. Hanson , Paul F. Bente, IV , Matthew J. Clemente , Antonio Ubach , Rajan Ramaswamy , Daniel S. Codd , Scott Beaver , Kevin L. Bokelman , Ian P. Dardani , Sean M. O'connor , Danielle Feldman
Abstract: Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device includes a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector defines a sterile fluid flowpath between the container and the insertion mechanism. A cannula initially disposed about the needle is included.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.014 seconds)
